HOXD13 and non-small cell lung carcinoma: In one study, higher levels of sPD-1 were associated with longer progression-free survival and OS in 38 patients with non-small cell lung cancer who were being treated with erlotinib, an inhibitor of mutated epidermal growth factor receptor [17].